Form 8-K

8-K — PALATIN TECHNOLOGIES INC

Accession: 0001493152-26-024219

Filed: 2026-05-18

Period: 2026-05-18

CIK: 0000911216

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000911216

2026-05-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 18, 2026

PALATIN

TECHNOLOGIES, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-15543

95-4078884

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

301

Carnegie Center Drive, Suite 304, Princeton, NJ

08540

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (609) 495-2200

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common

Stock, par value $0.01 per share

PTN

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01.

Notice

of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided

notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par

value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital

Market (the “Nasdaq”). The Nasdaq has approved such listing. The Company expects the listing and trading of its common stock

on the NYSE to cease at the close of trading on May 28, 2026. The Company expects the common stock to begin trading on the Nasdaq on

May 29, 2026. The common stock will continue to trade under the symbol “PTN”.

Item 7.01.

Regulation

FD Disclosure.

The

Company issued a press release on May 18, 2026 announcing the transfer of the listing of its common stock from the NYSE to Nasdaq. The

press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The

information in Item 7.01, including Exhibit 99.1, of this Current Report on Form 8-K is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities

Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by

specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated May 18, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

May 18, 2026

PALATIN

TECHNOLOGIES, INC.

/s/

Stephen T. Wills

Stephen

T. Wills, CPA, MST

Executive

Vice President, Chief Financial

Officer

and Chief Operating Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Palatin

to Begin Trading on Nasdaq Stock Exchange

PRINCETON,

NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on

the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock

has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from

the NYSE American.

The

Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol “PTN.”

Palatin’s common stock will continue to trade on the NYSE American until the market close on May 28, 2026.

“We

are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies,” said

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. “We believe the move to Nasdaq will improve the

visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”

Palatin

is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway, including hypothalamic

obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a focus on improved tolerability and long-term use. The Company’s

once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of calendar 2026,

and its oral MC4R selective agonist program continues to advance, with a next-generation oral candidate targeted for IND submission in

the first half of calendar 2027. Palatin’s development strategy is focused on advancing potential best-in-class MC4R candidates

designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and

support safe and effective long-term use.

action is required by existing stockholders with respect to the transfer of the Company’s listing.

About

Palatin

is a biopharmaceutical company developing medicines that target the melanocortin receptor system with targeted, receptor-specific product

candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to

develop products and then form collaborations with industry leaders to maximize their commercial potential. For more information, visit

the company’s website at www.palatin.com and follow us on X, formerly Twitter, @PalatinTech.

-More-

Forward-looking

Statements

in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such

as statements about the commencement of trading of Palatin’s common stock on the Nasdaq Capital Market. Palatin products in development,

clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product

candidates, and market potential for product candidates are “forward-looking statements” within the meaning of Section 27A

of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities

Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such

forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results

to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s

actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to,

results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin’s ability

to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to

complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical

and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with

the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

Investor

Inquiries:

Media

Inquiries:

Stephen

T. Wills, CPA, MST

Paul

Arndt, MBA, LifeSci Advisors, LLC

Chief

Financial Officer/Chief Operating Officer

Managing

Director

Tel:

(609) 495-2200 / Info@palatin.com

Tel:

(646) 597-6992 / Paul@LifeSciAdvisors.com

Palatin

Technologies® is a registered trademark of Palatin Technologies, Inc.

###

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 18

v3.26.1

Cover

May 18, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 18, 2026

Entity File Number

001-15543

Entity Registrant Name

PALATIN

TECHNOLOGIES, INC.

Entity Central Index Key

0000911216

Entity Tax Identification Number

95-4078884

Entity Incorporation, State or Country Code

Entity Address, Address Line One

301

Carnegie Center Drive

Entity Address, Address Line Two

Suite 304

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

(609)

Local Phone Number

495-2200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.01 per share

Trading Symbol

PTN

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration